Search Results Archives: May 2017

May 25, 2017

President Signals Intent To Work With Lawmakers On 340B Changes

Inside Health Policy posted an article titled, “President Signals Intent To Work With Lawmakers On 340B Changes.” The article reads as follows;

“The Trump administration wants to work with lawmakers on legislation to improve program integrity in the 340B drug discount program and provide the Health Resources and Services Administration more regulatory authority. HHS’ intentions are laid out in HRSA’s fiscal 2018 budget justification, though the budget includes few details on what such a package would include.

May 23, 2017

The Downward Spiral of the 340B Program

From Warren H. Fong, M.D., President of the Medical Oncology Association of Southern California

As the president of the Medical Oncology Association of Southern California and a practicing oncologist for nearly two decades, I have seen firsthand the negative impact the rapidly escalating abuse of the 340B Drug Pricing Program has had on cancer patients, healthcare costs and society. This growth has occurred without a proportional improvement in services to the poor and underserved — the very patients the program was designed to help. Contrary to former Rep. Henry Waxman’s (D-Calif.) analysis (“A program that works exactly as intended,” May 2), 340B is clearly broken).

May 22, 2017

Price Control Comment

340B Drug Pricing Program Ceiling Price and Manufacturer Civil Monetary Penalties Regulation;

SUMMARY: This document reopens the comment period for the June 17, 2015, proposed rule entitled ‘‘340B Drug Pricing Program Ceiling Price and Manufacturer Civil Monetary Penalties Regulation.’’ The comment period for the proposed rule, which ended on August 17, 2015, is reopened for 30 days.

Click here to view the comment.